In the latest trading session, Moderna (MRNA - Free Report) closed at $123, marking a +1.93% move from the previous day. This change outpaced the S&P 500's 0.04% loss on the day. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 2.93%.
Prior to today's trading, shares of the biotechnology company had lost 6.38% over the past month. This has lagged the Medical sector's gain of 2.28% and the S&P 500's gain of 4.22% in that time.
Wall Street will be looking for positivity from Moderna as it approaches its next earnings report date. In that report, analysts expect Moderna to post earnings of -$3.97 per share. This would mark a year-over-year decline of 175.76%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $288.81 million, down 93.92% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.16 per share and revenue of $6.47 billion, which would represent changes of -115.71% and -66.43%, respectively, from the prior year.
Any recent changes to analyst estimates for Moderna should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 11.4% lower. Moderna currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Moderna (MRNA - Free Report) closed at $123, marking a +1.93% move from the previous day. This change outpaced the S&P 500's 0.04% loss on the day. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 2.93%.
Prior to today's trading, shares of the biotechnology company had lost 6.38% over the past month. This has lagged the Medical sector's gain of 2.28% and the S&P 500's gain of 4.22% in that time.
Wall Street will be looking for positivity from Moderna as it approaches its next earnings report date. In that report, analysts expect Moderna to post earnings of -$3.97 per share. This would mark a year-over-year decline of 175.76%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $288.81 million, down 93.92% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.16 per share and revenue of $6.47 billion, which would represent changes of -115.71% and -66.43%, respectively, from the prior year.
Any recent changes to analyst estimates for Moderna should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 11.4% lower. Moderna currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MRNA - FREE